• Please ensure the correct institution details for NSLHD are included. These details can be found  here.
• Please email a word version of the CDA to [email protected]
• Please allow a minimum of 14 days for review and return of the CDA.

All clinical trials with an external sponsor must have a written agreement in place, to clarify the obligations, responsibilities and rights of the parties involved in the research. Please be advised that there are several different research agreement templates approved for use within a Public Health Organisation (PHO) and the Research Governance team strongly recommend the use of one of these. The use of non-standard agreements will require further review and could result in delays to authorisation.

Five CTRA templates have been approved for use in NSW PHOs and can be found here . Please contact the RGO for guidance on which template to use for your research.

Please note that any clauses included at Schedule 4 or 7 must be approved by the SEBS Committee and evidence of SEBS approval must be provided with the application.

Submission instructions:

• Researchers are strongly encouraged to submit the CTRA in draft (without signatures) to the RGO for review prior to governance submission. Please email the CTRA to [email protected], attention RGO.
• Please ensure the correct institution details for NSLHD are included on page 1. These details can be found here.
• Please be advised changes cannot be made to the standard clauses (pages 2-17).
• Please include the following wording in Schedule 2, 'payments':

All HREC and/or Research Governance fees will be paid by sponsor (or XXXXX) upon receipt of invoice. Costs can be found on the NSLHD Research Office website.

Sponsor (or XXXXX) will provide a Purchase Order (PO) number for inclusion on the invoice.

• Once reviewed and approved by the RGO, CTRAs must be signed by the Sponsor and Principal Investigator before submitting for review with the governance application through REGIS.
• Fully executed CTRAs will be signed and returned with project authorisation via REGIS.

A device trial is known as a 'clinical investigation' rather than a 'clinical trial'. The Medical Technology Association of Australia (MTAA) has developed a Clinical Investigation Research Agreements (CIRAs) and a Form of Indemnity (FoI) for use in commercially sponsored studies of medical technology. Please click here for further information on regulatory documents for use when conducting device trials including the MTAA Standard Clinical Research Investigation Agreement (CIRA) template.

When Investigator Initiated research involves a party external to NSLHD, an agreement may be required.

The NSLHD Research Office strongly recommends the use of one of the following templates for investigator initiated trials:

•  Clinical trial research agreement - For an investigator initiated study (please use for clinical trials)
•  Clinical research agreement - For an investigator initiated study (please use for other research)

• Researchers must submit the Research Agreement in draft (without signatures) to the RGO for review prior to SSA submission. Please email the agreement to [email protected], attention RGO.
• Please ensure the correct institution details for NSLHD are included on page 1. These details can be found  here.
• Please include the following wording in Schedule 2, 'payments':

All HREC and/or Research Governance fees will be paid by XXXXX upon receipt of invoice. Costs can be found on the NSLHD Research Office website.

For external payees, where an invoice will be issued, a Purchase Order (PO) number must be provided inclusion on the invoice.

• Once reviewed and approved by the RGO, CTRAs must be signed by the external party and Principal Investigator before submitting the agreement for review through REGIS. 
• Fully executed research agreements will be signed and returned with project authorisation via REGIS.

If your research involves a transfer of data, materials or samples (such as cell lines, blood, tissue, CT and MRI scans and other clinical data) from NSLHD to an external site and does not require a CTRA or other collaboration agreement a MTA may  be required.

It is strongly recommended that you contact the Research Office to ascertain this requirement.

The execution of a MTA incurs a fee. Please see our fee policy for details.

Submission instructions:

• The NSLHD MTA template can be found  here.
• Please note that only the highlighted text should be completed and changes should not be made to the standard terms and conditions.

Please note that any requested changes to the standard terms and conditions will require external review, will add additional delays to the review and may incur additional fees.

• It is strongly recommended that the draft MTA (without signatures) is submitted to the RGO for review prior to SSA submission. Please email the MTA to [email protected], attention RGO.

In order to conduct research, engagement of a service provider, without the service provider being a site, is sometimes required.
The Research Office have developed two CTSA templates.
The CTSA template for use when NSLHD intends on engaging the services of a provider can be found  here.
The CTSA template for use when NSLHD will be the service provider can be found  here.
The CTSA template is designed for use with one study only and not for on-going service provision.

For all commercially sponsored clinical trials a Medicines Australia Form of Indemnity  must be provided by the commercial sponsor on the Medicines Australia Form of Indemnity for Clinical Trials. The MTAA has forms of indemnity  available for commercially sponsored clinical investigations.

There are two forms of indemnity, standard and HREC only, available for use.

Form of Indemnity – HREC Review only

This form is to be submitted with the ethics application to NSLHD HREC when the ethics application is for a project that will be conducted outside of NSLHD. That is, NSLHD has no participating sites. 

Submission instructions:

• Please ensure the correct institution details for NSLHD are included on page 1. These details can be found  here.
• The Form of Indemnity – HREC Review only, must be signed by the sponsor before submitting the form with the ethics application through REGIS. 
• The form will be executed by NSLHD and returned via Regis with project approval.

Form of Indemnity - Standard

This form is to be submitted with the governance application when NSLHD is providing premises for the conduct of the study and HREC Review, or is providing premises only.

For all commercially sponsored clinical trials, an Insurance Certificate must be submitted with the governance application. Please refer to NSW MoH Policy  Clinical Trials – Insurance and Indemnity PD2011_006 , section 2.2.2 for further information on insurance requirements.

The Australian clinical trial sponsor must notify the TGA of the intent to sponsor a clinical trial involving an 'unapproved' therapeutic good prior to commencement of the use. The notification form must be submitted online and accompanied by the relevant fee. Please click here   for further information.

For investigator initiated research, where NSLHD will assume the role of sponsor, the CTN will be lodged by the Research Office, however it is the responsibility of the investigator to provide the information required for the CTN and pay the associated fee incurred by the TGA. Please complete the NSLHD eCTN summary, found here, and submit this to the Research Office with your governance application.